NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: IMARC Group

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group - Driven by a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015
DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group

 

NewswireTODAY - /newswire/ - Delhi, Noida, India, 2011/07/02 - Driven by a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

According to IMARC’s new research report “India Diabetes Market Report & Outlook for 2010-2015”, DPP-IV Inhibitors are expected to account for 17% of the total oral antidiabetics market by 2015. According to the research, there are currently three players operating in this market. MSD was the first to enter the market with its two drugs Januvia (Sitagliptin) and Janumet (Sitagliptin+Metformin), and represents the current market leader. The other two Players are Novartis and local manufacturer USV. Both players have tied up to market Galvus (Vidagliptin) and Eucreas (Vidagliptin+Metformin) in the Indian market.

The research thoroughly investigates the factors which will drive the growth of DPP-IV inhibitors and other oral antidiabetic drugs in India. Analysts from IMARC believe that despite the fact that DPP-IV inhibitors are more expensive than conventional oral antidiabetic drugs such as Biguanides and Sulphonylureas, there is still a significant patient population that can afford high priced innovative drugs in India. According to IMARC, the high safety-efficacy profile associated with DPP-IV Inhibitors, coupled with their rich pipeline will be a key factor in driving the growth of this market in the next five years.

Findings from the research suggest that apart from the four products already available, three new DPP-IV Inhibitors will be launched in India in the next five years. IMARC expects the DPP-IV Inhibitor market to reach sales worth more than US$ 163 Million by 2015.


“Indian Diabetes Market Report and Outlook for 2010-2015” gives a deep insight into the Indian diabetes market. The research study serves as an analytical as well as a statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in India. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Indian diabetes market in some form or the other.

Table of Contents

1. Executive Summary
2. Diabetes Disease Overview
2.1 What Is Diabetes?
2.2 Diabetes Diagnosis And Treatment
2.2.1 Diagnosis
2.2.2 Treatment
2.3 Diabetes Complications

3. Why Is The Diabetes Market So Lucrative In India
3.1 India Has The Largest Diabetic Population In The World.
3.2 India Represents One Of The Fastest Growing Markets Globally
3.3 Improving Diagnosis And Treatment Rates
3.4 Large Untapped Market
3.5 Bright Outlook For Innovative Drugs

4. The Indian Diabetes Epidemiology
4.1 Total Prevalence
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban And Rural Prevalence
4.1.3 Prevalence Of Diabetes By Sex
4.1.4 Prevalence Of Diabetes By Age Group
4.1.5 Prevalence Of Diabetes In Various Regions In India
4.2 Diagnosis And Treatment Rates In India

5. The Indian Diabetes Market
5.1 Market Trend (2005-2009)
5.2 Market Segmentation (2005-2009)
5.3 Market Forecasts (2010-2015)

6. The Indian Non-insulin Anti-diabetics Market
6.1 Market Trend (2005-2009)
6.2 Competitive Landscape (2005-2009)
6.3 Market Forecasts (2010-2015)
6.4 Market Segmentation (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.2.1 Share Of Key Players
6.4.1.2.2 Portfolio Of Key Players
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.2.1 Share Of Key Players
6.4.2.2.2 Portfolio Of Key Players
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.2.1 Share Of Key Players
6.4.3.2.2 Portfolio Of Key Players
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.2.1 Share Of Key Players
6.4.4.2.2 Portfolio Of Key Players
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-iv Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.2.1 Share Of Key Players
6.4.5.2.2 Portfolio Of Key Players
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.2.1 Share Of Key Players
6.4.6.2.2 Portfolio Of Key Players
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.2.1 Share Of Key Players
6.4.7.2.2 Portfolio Of Key Players
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All Other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.2.1 Share Of Key Players
6.4.8.2.2 Portfolio Of Key Players
6.4.8.3 Market Forecasts (2010-2015)

7. The Indian Insulin Market
7.1 Market Trend (2005-2009)
7.2 Market Segmentation By Molecule (2005-2009)
7.3 Market Segmentation By Mode Of Action
7.4 Competitive Landscape
7.4.1 Share Of Key Players
7.4.2 Portfolio Of Key Players
7.5 Market Forecasts (2010-2015)

8. Road Blocks
8.1 Low Average Per Patient Spending On Diabetes Drugs
8.2 Preference For Inexpensive And Older Drug Classes
8.3 Highly Fragmented And ‘genericized’ Market
8.4 Low Rates Of Drug Treated Population In Rural Areas.

To buy the complete report or to get a free sample:

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) or email sales[.]imarcgroup.com or visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


DPP-IV Inhibitors to Account for 17% of the Indian Oral Antidiabetics Market by 2015 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

Nexans Invests in its Draveil Site to Double Production Capacity of Medical Cables
SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
Tongue-operated AI-powered Device that Aims to Challenge Neuralink, Wins Red Dot 2024 Award
Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories
Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
Cancer Treatment Using Rotating Gantry of the Toshiba Heavy Ion Therapy System Starts At Yonsei University Health System
Bruker's Canopy Biosciences Announces the Launch of CellScape™ Whole-Slide Imaging Chamber for Spatial Biology
iSono Health Applauded by Frost & Sullivan for Ensuring Patient Comfort and Safety Providing Quality Imaging & Diagnosis with its iSono Health ATUSA
Bruker Launches the New BEAM, a Dedicated Single-Point FT-NIR Spectrometer Designed for In-Process Control
Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery At SLAS2024
Yokogawa Introduces CellVoyager High-Content Analysis System CQ3000
Advantech Introduces Cutting-Edge Solutions to Address Diverse Imaging Needs in Operating Rooms - The AVAS-2 Series for 4K Streaming Excellence
Seno Medical Earns Frost & Sullivan’s 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis
Withings Announces BeamO The Revolutionary At-home Health Checkup
Advancing GLP-1 Treatments, Insulin, and Large-volume Injections with Ready-to-use Cartridges from SCHOTT Pharma

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)